Spaulding Clinical to Offer ADME Clinical Trial Services
Addition solidifies commitment to delivering comprehensive solutions worldwide, company says.
Spaulding Clinical, a clinical research organization (CRO), has announced the addition of ADME (absorption, distribution, metabolism, and excretion) clinical trials to its list of services. According to the company, ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body.
“With the addition of ADME studies to our suite of services plus hired staff with over 60 years combined experience in conducting these trial types, Spaulding Clinical is positioned to better support our clients in making informed decisions during drug development,” said Cassandra Erato, CEO, Spaulding Clinical. “These trials play a pivotal role in understanding the behavior and fate of a drug in the body, allowing researchers to optimize dosage, assess potential drug-drug interactions, and enhance overall drug safety profiles.”
Reference: Spaulding Clinical Expands Services to Include ADME Clinical Trials. Spaulding Clinical. June 22, 2023.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
